Targeting the A3 Adenosine Receptor for the Treatment of Advanced Liver Cancer

Time: 2:45 pm
day: Day Two


• Understanding the rational of targeting the A3 adenosine receptor for the treatment of liver cancer

• Utilizing the highly specific A3 adenosine receptor agonist namodenoson to inhibit liver cancer growth

• Exploring the phase 2 study data and the phase 3 pivotol study protocol